| HOME >> BIOLOGY >> TECHNOLOGY |
Deficit, beginning of
period (127,817) (111,151) (124,717) (108,665)
-------------------------------------------------------------------------
Deficit, end of period $(130,814) $(114,863) $(130,814) $(114,863)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted loss
per common share $(0.03) $(0.05) $(0.06) $(0.08)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted avg. number of
common shares outstanding
(000's) 94,464 74,505 94,464 74,202
-------------------------------------------------------------------------
-------------------------------------------------------------------------
STATEMENTS OF CASH FLOWS
Unaudited - In Thousands
of Canadian dollars 2007 2006 2007 2006
----------------------------------------------
Loss for the period $(2,997) $(3,712) $(6,097) $(6,198)
Items not affecting cash:
Amortization 117 233 254 459
Stock-based compensation 52 88 185 235
Issuance of deferred
share units - 96 - 96
Accretion of convertible
royalty participation
units 425 419 846 719
Changes in non-cash
working capital items
relating to operating
activities 274 619 261 (676)
------------------------------------------------------
'/>"/>
| SOURCE MIGENIX Inc. Copyright©2007 PR Newswire. All rights reserved |